128 related articles for article (PubMed ID: 22488710)
1. Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation.
Chiu HY; Sun GH; Chen SY; Wang HH; Ho MY; Chu CY; Wu WL; Jhou RS; Tsai YL; Huang RT; Sun KH; Tang SJ
Mol Carcinog; 2013 Sep; 52(9):705-14. PubMed ID: 22488710
[TBL] [Abstract][Full Text] [Related]
2. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
3. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.
Fingleton B; Carter KJ; Matrisian LM
Cancer Res; 2007 May; 67(10):4800-6. PubMed ID: 17510409
[TBL] [Abstract][Full Text] [Related]
4. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
[TBL] [Abstract][Full Text] [Related]
5. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
[TBL] [Abstract][Full Text] [Related]
6. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
7. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
9. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
10. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
11. Activated T cell exosomes promote tumor invasion via Fas signaling pathway.
Cai Z; Yang F; Yu L; Yu Z; Jiang L; Wang Q; Yang Y; Wang L; Cao X; Wang J
J Immunol; 2012 Jun; 188(12):5954-61. PubMed ID: 22573809
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
Drozdzik M; Qian C; Lasarte JJ; Bilbao R; Prieto J
Gene Ther; 1998 Dec; 5(12):1622-30. PubMed ID: 10023441
[TBL] [Abstract][Full Text] [Related]
14. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
Zhu Q; Liu JY; Yang CM; Xu HW; Zhang AZ; Cui Y; Wang HB; Qin CY; Li YQ
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1071-7. PubMed ID: 16957513
[TBL] [Abstract][Full Text] [Related]
15. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
16. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand on tumor cells mediates inactivation of neutrophils.
Chen YL; Chen SH; Wang JY; Yang BC
J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204
[TBL] [Abstract][Full Text] [Related]
18. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
Zhang J; Xu G
Cancer Genet Cytogenet; 2007 Dec; 179(2):112-7. PubMed ID: 18036397
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of recombinant human interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis.
Li CG; Li ML; Shu XH; Liu YJ; Wu WS
Cancer Chemother Pharmacol; 2010 Oct; 66(5):981-6. PubMed ID: 20499068
[TBL] [Abstract][Full Text] [Related]
20. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
